Filing Details

Accession Number:
0000903423-15-000581
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-10-07 16:31:39
Reporting Period:
2015-10-07
Filing Date:
2015-10-07
Accepted Time:
2015-10-07 16:31:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1583107 Theravance Biopharma Inc. TBPH Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1131399 Plc Glaxosmithkline 980 Great West Road
Brentford, Middlesex, X0 TW8 9GS
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2015-10-07 44,574 $607,543.62 8,343,792 No 4 P Indirect By Corporation
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Corporation
Footnotes
  1. Ordinary shares purchased pursuant to the right of Glaxo Group Limited ("GGL"), an indirect wholly owned subsidiary of the Reporting Person, under Section 2.1(d)(ii) of the Governance Agreement by and among Theravance Biopharma, Inc. (the "Issuer") and GGL, dated as of March 3, 2014. Pursuant to Section 2.1(d)(ii), GGL has the right to purchase from the Issuer, on a quarterly basis, sufficient ordinary shares to maintain its ownership percentage in the Issuer taking into account the preceding quarter's option exercise and equity vesting activity.
  2. Ordinary Shares are held of record by GGL, an indirect wholly owned subsidiary of the Reporting Person.